ATE420201T1 - Nachweis der cox-2 aktivität und von anandamid- metaboliten - Google Patents

Nachweis der cox-2 aktivität und von anandamid- metaboliten

Info

Publication number
ATE420201T1
ATE420201T1 AT01963833T AT01963833T ATE420201T1 AT E420201 T1 ATE420201 T1 AT E420201T1 AT 01963833 T AT01963833 T AT 01963833T AT 01963833 T AT01963833 T AT 01963833T AT E420201 T1 ATE420201 T1 AT E420201T1
Authority
AT
Austria
Prior art keywords
cox
activity
detection
kits
prostaglandin
Prior art date
Application number
AT01963833T
Other languages
English (en)
Inventor
Lawrence Marnett
Kevin Kozak
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Application granted granted Critical
Publication of ATE420201T1 publication Critical patent/ATE420201T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01963833T 2000-08-07 2001-08-07 Nachweis der cox-2 aktivität und von anandamid- metaboliten ATE420201T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22366500P 2000-08-07 2000-08-07
US30297501P 2001-07-03 2001-07-03

Publications (1)

Publication Number Publication Date
ATE420201T1 true ATE420201T1 (de) 2009-01-15

Family

ID=26918005

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01963827T ATE421595T1 (de) 2000-08-07 2001-08-07 Zusammensetzungen und verfahren zum nachweis und zur quantifizierung von cox-2-aktivität und 2- arachidonylglycerin-metaboliten
AT01963833T ATE420201T1 (de) 2000-08-07 2001-08-07 Nachweis der cox-2 aktivität und von anandamid- metaboliten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01963827T ATE421595T1 (de) 2000-08-07 2001-08-07 Zusammensetzungen und verfahren zum nachweis und zur quantifizierung von cox-2-aktivität und 2- arachidonylglycerin-metaboliten

Country Status (7)

Country Link
US (3) US20020106707A1 (de)
EP (2) EP1307585B1 (de)
AT (2) ATE421595T1 (de)
AU (3) AU8475301A (de)
CA (2) CA2422306A1 (de)
DE (2) DE60137512D1 (de)
WO (2) WO2002012445A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123970A1 (en) * 2001-04-25 2005-06-09 Can Ozbal High throughput autosampler
US8414774B2 (en) * 2001-04-25 2013-04-09 Agilent Technologies, Inc. Systems and methods for high-throughput screening of fluidic samples
AU2002354901A1 (en) * 2001-07-16 2003-03-03 Edward Hogestatt Compounds with analgesic, antipyretic and/or anti-inflammatory activity
US6864282B2 (en) * 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
US20050031537A1 (en) * 2002-08-22 2005-02-10 Dannenberg Andrew J. Multifunctional COX-2 inhibitors
NO20035683D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av prostatakreft
GB0402719D0 (en) * 2004-02-07 2004-03-10 Royal College Of Surgeons Ie A method of detecting incomplete inhibition of enzymes in individuals undergoing enzyme inhibitor therapy
WO2006047466A2 (en) 2004-10-21 2006-05-04 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8677808B2 (en) * 2007-11-02 2014-03-25 Agilent Technologies, Inc. Sample injection system
WO2009105481A1 (en) * 2008-02-19 2009-08-27 The Buck Institute For Age Research Mao-b elevation as an early parkinson's disease biomarker
WO2014015341A2 (en) * 2012-07-20 2014-01-23 Vanderbilt University Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation
CN106999464A (zh) * 2014-12-09 2017-08-01 雀巢产品技术援助有限公司 生物活性脂质的用途
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
ES2953032T3 (es) * 2017-09-01 2023-11-07 Univ East Carolina Métodos ex vivo para la activación de las células inmunológicas
CN109900830B (zh) * 2019-04-02 2021-07-23 天地恒一制药股份有限公司 采用hplc分离测定塞来昔布中磺酰胺类杂质的方法及应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632627A (en) 1968-01-05 1972-01-04 Smith Kline French Lab Glyceride derivatives of prostaglandins
JPS4920766B1 (de) 1970-11-10 1974-05-27
CA932324A (en) 1971-10-22 1973-08-21 Gordon Maxwell Glyceride and phosphatide derivatives of prostaglandins
JPS59156299A (ja) * 1983-02-28 1984-09-05 Noda Sangyo Kagaku Kenkyusho Ｎ−アセチルヘキソサミンの定量法及びその定量用試薬
US4675281A (en) 1984-07-09 1987-06-23 Lands William E M Quantification of hydroperoxides using prostaglandin H synthase
US5362476A (en) * 1984-10-18 1994-11-08 Board Of Regents, The University Of Texas System Alkyl phosphonate polyazamacrocyclic cheates for MRI
US5047354A (en) 1987-10-30 1991-09-10 Foegh Marie L Thromboxane B2 assay for coronary artery thrombosis
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
WO1992022668A1 (en) 1991-06-14 1992-12-23 Vanderbilt University Method and compositions to assess oxidative stress in vivo
US5858696A (en) 1991-06-14 1999-01-12 Vanderbilt University Method and compositions to assess oxidative stress in vivo
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5589575A (en) 1992-07-23 1996-12-31 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture Purification of hapten-carrier generated antibodies
US5837479A (en) 1992-09-22 1998-11-17 Young; Donald A. Screening assays for inhibitors of mammalian prostaglandin H synthase-2
DE59202364D1 (de) 1992-10-21 1995-06-29 Edith Dr Dr Huland Verfahren zur quantitativen Bestimmung von krankheitsspezifischen Antigenen und Vorrichtung zur Durchführung des Verfahrens.
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US5995645A (en) 1993-08-18 1999-11-30 Applied Spectral Imaging Ltd. Method of cancer cell detection
US5475021A (en) 1993-12-03 1995-12-12 Vanderbilt University Compounds and compositions for inhibition of cyclooxygenase activity
US5459239A (en) 1994-01-24 1995-10-17 Merck Frosst Canada Inc. Peptide sequences and antipeptide antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2 proteins
US5686269A (en) * 1994-07-28 1997-11-11 The Mclean Hospital Corporation Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid
US5999843A (en) 1995-01-03 1999-12-07 Omnicorder Technologies, Inc. Detection of cancerous lesions by their effect on the spatial homogeneity of skin temperature
US5731343A (en) 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
FR2732597B1 (fr) * 1995-04-05 1997-05-16 Oreal Utilisation dans une composition en tant qu'activateur et/ou stabilisateur de cyclooxygenase d'au moins un derive de pyrimidine substitue en 6
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
KR19990064310A (ko) 1995-10-17 1999-07-26 윌리암스 로저 에이 시클로옥시게나제-2의 검출방법
US5945675A (en) 1996-03-18 1999-08-31 Pacific Northwest Research Foundation Methods of screening for a tumor or tumor progression to the metastatic state
US5891622A (en) 1996-09-30 1999-04-06 Oxford Biomedical Research, Inc. Assessment of oxidative stress in vivo
IL121659A (en) 1996-10-25 2000-07-16 Bayer Ag Method for determining CPSA in a blood sample
US5973191A (en) 1996-12-30 1999-10-26 Vanderbilt University Selective inhibitors of prostaglandin endoperoxide synthase-2
DZ2479A1 (fr) 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US5874235A (en) * 1997-07-18 1999-02-23 The Johns Hopkins University Screening assays for cancer chemopreventative agents
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use

Also Published As

Publication number Publication date
DE60137512D1 (de) 2009-03-12
WO2002012549A1 (en) 2002-02-14
WO2002012445A1 (en) 2002-02-14
AU8475301A (en) 2002-02-18
AU2001284753B2 (en) 2006-10-26
EP1307538B1 (de) 2009-01-07
EP1307585A4 (de) 2005-03-02
EP1307585A1 (de) 2003-05-07
CA2422306A1 (en) 2002-02-14
US20020064804A1 (en) 2002-05-30
US7628975B2 (en) 2009-12-08
EP1307538A1 (de) 2003-05-07
ATE421595T1 (de) 2009-02-15
US20060110786A1 (en) 2006-05-25
US7189504B2 (en) 2007-03-13
EP1307585B1 (de) 2009-01-21
AU8474701A (en) 2002-02-18
DE60137335D1 (de) 2009-02-26
US20020106707A1 (en) 2002-08-08
EP1307538A4 (de) 2005-03-02
CA2422803A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
ATE420201T1 (de) Nachweis der cox-2 aktivität und von anandamid- metaboliten
Milne et al. Measurement of F2-isoprostanes and isofurans using gas chromatography–mass spectrometry
Haan et al. A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background
Kadiiska et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?
DE60134957D1 (de) Methoden und testsätze für annäherungstest
DK1381697T3 (da) Cirkulær probe-amplifikation (CPA) af ringformede nukleinsyremolekyler
JP2004503760A5 (de)
RU2003100531A (ru) Композиции, содержащие краситель на основе производного мочевины, для выявления аналита, и способы их использования
DK420387D0 (da) Fremgangsmaade og hybridiseringsproevesaet til paavisning af en nucleotidmaalsekvens
ATE509275T1 (de) Schnelltest für glykiertes albumin
ATE443775T1 (de) Hif-prolylhydroxylase-aktivitätstest
WO2007120699A3 (en) Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals
DE69842017D1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
WO2004027378A3 (en) Luminescence-based methods and probes for measuring cytochrome p450 activity
Yuan et al. Subsecond absolute quantitation of amine metabolites using isobaric tags for discovery of pathway activation in mammalian cells
DK1639130T3 (da) Prober, biblioteker og kits til analyse af blandinger af nukleinsyrer og metoder til opbygning af disse
BR0101294A (pt) Métodos de triagem de um composto que modula a atividade do canal de cálcio, e para bloqueadores e para estimuladores de icrac, kit para uso em um método, célula sanguìnea ou célula derivada do sangue, linfócito ou célula derivada de linfócito, ou mastócito ou célula derivada de mastócito, e, população de células imunes de roedores
BRPI0513596B8 (pt) método e kit para detectar uma infecção micobacteriana em uma amostra de um indivíduo de interesse por meio da detecção de antígeno micobacteriano
RU2016143733A (ru) Применение абсорбирующих частиц для усовершенствования обнаружения сигнала в способе анализа
Shin et al. Evaluation of an LC–MS/MS assay for 15N-nitrite for cellular studies of l-arginine action
NO20073524L (no) En metode for differensiering mellom blod og kontrollopplosninger som inneholder en vanlig analytt
Zimmermann et al. Nutrient deprivation in neuroblastoma cells alters 4-hydroxynonenal-induced stress response
FR2384261A1 (fr) Composition a base d'un hydroperoxyde, dispositif et methode pour le dosage de substances a action de peroxydase
FR2798392B1 (fr) Marqueurs genetiques de la toxicite, preparation et utilisations
Zhou et al. Determination of two major metabolites of the novel anti-tumour agent 5, 6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties